{"doc_id": "33278747", "type of study": "Therapy", "title": "", "abstract": "Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study.\nWe have previously hypothesized that pentoxifylline could be beneficial for the treatment of COVID-19 given its potential to restore the immune response equilibrium, reduce the impact of the disease on the endothelium and alveolar epithelial cells, and improve the circulatory function.\nSerum lactate dehydrogenase (LDH) and lymphocyte count are accessible biomarkers that correlate with the severity of COVID-19, the need for hospitalization, and mortality, reflecting the host immune response's contribution to the seriousness of SARS-CoV-2 infection.\nWe carried out this external pilot study on 38 patients with moderate and severe COVID-19 to test the effect pentoxifylline on parameters such as LDH, lymphocyte count, days of hospitalization, mortality, and proportion of patients requiring intubation.\nTwenty-six patients were randomized to receive 400\u00a0mg of pentoxifylline t.i.d.\nplus standard therapy (pentoxifylline group), while the rest received the standard treatment (control group).\nLinear regression models were built for statistically significant parameters.\nPentoxifylline treatment was associated with a 64.25% increase (CI95% 11.83, 116.68) in lymphocyte count and a 29.61% decrease (CI95% 15.11, 44.10) in serum LDH.\nAlthough a trend towards reduced days of hospitalization, mortality, and proportion of patients requiring intubation was observed, no statistically significant difference was found for these parameters.\nOur findings open the possibility of pentoxifylline being repositioned as a drug for COVID-19 treatment with the advantages of a proven safety profile, availability, and no risk of immunosuppression; however, this evidence needs to be confirmed in a pragmatic randomized controlled trial.\nCopyright \u00a9 2020 Elsevier B.V. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 76, "end": 84}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 93, "end": 101}, {"term": "moderate and severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 89}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients : Results from an external pilot study .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 76, "end": 84}], "Intervention": [{"term": "Pentoxifylline", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 14, "has_chemical": [{"text": "pentoxifylline", "maps_to": "C0030899:pentoxifylline", "start": 0, "end": 14}], "has_relation": "N/A"}], "Outcome": [{"term": "serum LDH levels", "negation": "affirmed", "UMLS": {}, "start": 25, "end": 41}, {"term": "lymphocyte count", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 72}], "Observation": [{"term": "decreases", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 24}, {"term": "increases", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 55}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "We have previously hypothesized that pentoxifylline could be beneficial for the treatment of COVID-19 given its potential to restore the immune response equilibrium , reduce the impact of the disease on the endothelium and alveolar epithelial cells , and improve the circulatory function .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 93, "end": 101}], "Intervention": [{"term": "pentoxifylline", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 51, "has_chemical": [{"text": "pentoxifylline", "maps_to": "C0030899:pentoxifylline", "start": 0, "end": 14}], "has_relation": "N/A"}], "Outcome": [], "Observation": [{"term": "beneficial", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 71}, {"term": "reduce", "negation": "affirmed", "UMLS": {}, "start": 167, "end": 173}, {"term": "improve", "negation": "affirmed", "UMLS": {}, "start": 255, "end": 262}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Serum lactate dehydrogenase ( LDH ) and lymphocyte count are accessible biomarkers that correlate with the severity of COVID-19 , the need for hospitalization , and mortality , reflecting the host immune response 's contribution to the seriousness of SARS-CoV-2 infection .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "We carried out this external pilot study on 38 patients with moderate and severe COVID-19 to test the effect pentoxifylline on parameters such as LDH , lymphocyte count , days of hospitalization , mortality , and proportion of patients requiring intubation .", "Evidence Elements": {"Participant": [{"term": "moderate and severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 89}], "Intervention": [{"term": "pentoxifylline", "negation": "affirmed", "UMLS": {}, "start": 109, "end": 123, "has_chemical": [{"text": "pentoxifylline", "maps_to": "C0030899:pentoxifylline", "start": 0, "end": 14}], "has_relation": "N/A"}], "Outcome": [{"term": "parameters", "negation": "affirmed", "UMLS": {}, "start": 127, "end": 137}, {"term": "LDH", "negation": "affirmed", "UMLS": {}, "start": 146, "end": 149}, {"term": "lymphocyte count", "negation": "affirmed", "UMLS": {}, "start": 152, "end": 168}, {"term": "days of hospitalization", "negation": "affirmed", "UMLS": {}, "start": 171, "end": 194}, {"term": "mortality", "negation": "affirmed", "UMLS": {}, "start": 197, "end": 206}, {"term": "proportion", "negation": "affirmed", "UMLS": {}, "start": 213, "end": 223}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Twenty-six patients were randomized to receive 400 mg of pentoxifylline t.i.d .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "pentoxifylline", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 71, "has_chemical": [{"text": "pentoxifylline", "maps_to": "C0030899:pentoxifylline", "start": 0, "end": 14}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "plus standard therapy ( pentoxifylline group ) , while the rest received the standard treatment ( control group ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "standard therapy", "negation": "affirmed", "UMLS": {}, "start": 5, "end": 21, "has_procedure": [{"text": "standard therapy", "maps_to": "C2936643:standard therapy", "start": 0, "end": 16}], "has_relation": "N/A"}, {"term": "standard", "negation": "affirmed", "UMLS": {}, "start": 5, "end": 13, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Linear regression models were built for statistically significant parameters .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Pentoxifylline treatment was associated with a 64.25 % increase ( CI95 % 11.83 , 116.68 ) in lymphocyte count and a 29.61 % decrease ( CI95 % 15.11 , 44.10 ) in serum LDH .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Pentoxifylline", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 14, "has_chemical": [{"text": "pentoxifylline", "maps_to": "C0030899:pentoxifylline", "start": 0, "end": 14}], "has_relation": "N/A"}], "Outcome": [{"term": "lymphocyte count", "negation": "affirmed", "UMLS": {}, "start": 93, "end": 109}], "Observation": [{"term": "64.25 % increase", "negation": "affirmed", "UMLS": {}, "start": 47, "end": 63}, {"term": "29.61 % decrease", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 132}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "Pentoxifylline", "has_chemical": [{"text": "pentoxifylline", "maps_to": "C0030899:pentoxifylline", "start": 0, "end": 14}], "has_relation": "N/A"}, "Observation": "64.25 % increase", "Outcome": "lymphocyte count", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Although a trend towards reduced days of hospitalization , mortality , and proportion of patients requiring intubation was observed , no statistically significant difference was found for these parameters .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "days of hospitalization", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 56}, {"term": "mortality", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 68}, {"term": "proportion of patients requiring intubation", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 118}], "Observation": [{"term": "trend towards reduced", "negation": "affirmed", "UMLS": {}, "start": 11, "end": 32}, {"term": "statistically significant difference", "negation": "negated", "UMLS": {}, "start": 137, "end": 173}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "statistically significant difference", "Outcome": "mortality", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Our findings open the possibility of pentoxifylline being repositioned as a drug for COVID-19 treatment with the advantages of a proven safety profile , availability , and no risk of immunosuppression ; however , this evidence needs to be confirmed in a pragmatic randomized controlled trial .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Elsevier B.V . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}